Research ExplorerPublicationsHexyl aminolevulinate-guided fluorescence cystoscopy in the ...

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature

Standard

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature. / Rink, Michael; Babjuk, Marko; Catto, James W F; Jichlinski, Patrice; Shariat, Shahrokh F; Stenzl, Arnulf; Stepp, Herbert; Zaak, Dirk; Witjes, J Alfred.

In: EUR UROL, Vol. 64, No. 4, 01.10.2013, p. 624-38.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rink, M, Babjuk, M, Catto, JWF, Jichlinski, P, Shariat, SF, Stenzl, A, Stepp, H, Zaak, D & Witjes, JA 2013, 'Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature', EUR UROL, vol. 64, no. 4, pp. 624-38. https://doi.org/10.1016/j.eururo.2013.07.007

APA

Rink, M., Babjuk, M., Catto, J. W. F., Jichlinski, P., Shariat, S. F., Stenzl, A., Stepp, H., Zaak, D., & Witjes, J. A. (2013). Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature. EUR UROL, 64(4), 624-38. https://doi.org/10.1016/j.eururo.2013.07.007

Vancouver

Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature. EUR UROL. 2013 Oct 1;64(4):624-38. https://doi.org/10.1016/j.eururo.2013.07.007

Bibtex

@article{6f6c6428e94d4a6690e5777322fa1805,
title = "Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature",
abstract = "CONTEXT: Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC).OBJECTIVE: To systematically evaluate evidence regarding the therapeutic benefits and economic considerations of PDD in NMIBC detection and treatment.EVIDENCE ACQUISITION: We performed a critical review of PubMed/Medline, Embase, and the Cochrane Library in October 2012 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) and Standards for the Reporting of Diagnostic Accuracy Studies (STARD) criteria. Forty-four publications were selected for inclusion in this analysis.EVIDENCE SYNTHESIS: Included reports used 5-ALA (in 26 studies), HAL (15 studies), or both (three studies) as photosensitising agents. PDD increased the detection of both papillary tumours (by 7-29%) and flat carcinoma in situ (CIS; by 25-30%) and reduced the rate of residual tumours after transurethral resection of bladder tumour (TURBT; by an average of 20%) compared to WLC alone. Superior recurrence-free survival (RFS) rates and prolonged RFS intervals were reported for PDD, compared to WLC in most studies. PDD did not appear to reduce disease progression. Our findings are limited by tumour heterogeneity and a lack of NMIBC risk stratification in many reports or adjustment for intravesical therapy use in most studies. Although cost effectiveness has been demonstrated for 5-ALA, it has not been studied for HAL.CONCLUSIONS: Moderately strong evidence exists that PDD improves tumour detection and reduces residual disease after TURBT compared with WLC. This has been shown to improve RFS but not progression to more advanced disease. Further work to evaluate cost effectiveness of PDD is required.",
keywords = "Aminolevulinic Acid, Cost-Benefit Analysis, Cystectomy, Cystoscopy, Disease-Free Survival, Health Care Costs, Humans, Neoplasm Invasiveness, Neoplasm, Residual, Photosensitizing Agents, Predictive Value of Tests, Risk Factors, Time Factors, Treatment Outcome, Urinary Bladder, Urinary Bladder Neoplasms",
author = "Michael Rink and Marko Babjuk and Catto, {James W F} and Patrice Jichlinski and Shariat, {Shahrokh F} and Arnulf Stenzl and Herbert Stepp and Dirk Zaak and Witjes, {J Alfred}",
note = "Copyright {\textcopyright} 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2013",
month = oct,
day = "1",
doi = "10.1016/j.eururo.2013.07.007",
language = "English",
volume = "64",
pages = "624--38",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature

AU - Rink, Michael

AU - Babjuk, Marko

AU - Catto, James W F

AU - Jichlinski, Patrice

AU - Shariat, Shahrokh F

AU - Stenzl, Arnulf

AU - Stepp, Herbert

AU - Zaak, Dirk

AU - Witjes, J Alfred

N1 - Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - CONTEXT: Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC).OBJECTIVE: To systematically evaluate evidence regarding the therapeutic benefits and economic considerations of PDD in NMIBC detection and treatment.EVIDENCE ACQUISITION: We performed a critical review of PubMed/Medline, Embase, and the Cochrane Library in October 2012 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) and Standards for the Reporting of Diagnostic Accuracy Studies (STARD) criteria. Forty-four publications were selected for inclusion in this analysis.EVIDENCE SYNTHESIS: Included reports used 5-ALA (in 26 studies), HAL (15 studies), or both (three studies) as photosensitising agents. PDD increased the detection of both papillary tumours (by 7-29%) and flat carcinoma in situ (CIS; by 25-30%) and reduced the rate of residual tumours after transurethral resection of bladder tumour (TURBT; by an average of 20%) compared to WLC alone. Superior recurrence-free survival (RFS) rates and prolonged RFS intervals were reported for PDD, compared to WLC in most studies. PDD did not appear to reduce disease progression. Our findings are limited by tumour heterogeneity and a lack of NMIBC risk stratification in many reports or adjustment for intravesical therapy use in most studies. Although cost effectiveness has been demonstrated for 5-ALA, it has not been studied for HAL.CONCLUSIONS: Moderately strong evidence exists that PDD improves tumour detection and reduces residual disease after TURBT compared with WLC. This has been shown to improve RFS but not progression to more advanced disease. Further work to evaluate cost effectiveness of PDD is required.

AB - CONTEXT: Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC).OBJECTIVE: To systematically evaluate evidence regarding the therapeutic benefits and economic considerations of PDD in NMIBC detection and treatment.EVIDENCE ACQUISITION: We performed a critical review of PubMed/Medline, Embase, and the Cochrane Library in October 2012 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) and Standards for the Reporting of Diagnostic Accuracy Studies (STARD) criteria. Forty-four publications were selected for inclusion in this analysis.EVIDENCE SYNTHESIS: Included reports used 5-ALA (in 26 studies), HAL (15 studies), or both (three studies) as photosensitising agents. PDD increased the detection of both papillary tumours (by 7-29%) and flat carcinoma in situ (CIS; by 25-30%) and reduced the rate of residual tumours after transurethral resection of bladder tumour (TURBT; by an average of 20%) compared to WLC alone. Superior recurrence-free survival (RFS) rates and prolonged RFS intervals were reported for PDD, compared to WLC in most studies. PDD did not appear to reduce disease progression. Our findings are limited by tumour heterogeneity and a lack of NMIBC risk stratification in many reports or adjustment for intravesical therapy use in most studies. Although cost effectiveness has been demonstrated for 5-ALA, it has not been studied for HAL.CONCLUSIONS: Moderately strong evidence exists that PDD improves tumour detection and reduces residual disease after TURBT compared with WLC. This has been shown to improve RFS but not progression to more advanced disease. Further work to evaluate cost effectiveness of PDD is required.

KW - Aminolevulinic Acid

KW - Cost-Benefit Analysis

KW - Cystectomy

KW - Cystoscopy

KW - Disease-Free Survival

KW - Health Care Costs

KW - Humans

KW - Neoplasm Invasiveness

KW - Neoplasm, Residual

KW - Photosensitizing Agents

KW - Predictive Value of Tests

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Urinary Bladder

KW - Urinary Bladder Neoplasms

U2 - 10.1016/j.eururo.2013.07.007

DO - 10.1016/j.eururo.2013.07.007

M3 - SCORING: Journal article

C2 - 23906669

VL - 64

SP - 624

EP - 638

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 4

ER -